Published in Hepatitis Weekly, June 8th, 2009
"Here, we report for the first time on the distribution and occurrence of TA and NOSA before, during, and after treatment with daily high-dosed IFN alfacon-1 [consensus IFN (CIFN)]. Thyrotropin (TSH) levels and antibodies to different autoantigens were analyzed in 217 patients with CHC (29.8% females) who were treated with CIFN...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.